Shanghai Simnova Biotechnology Co.,Ltd.
9
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
Role: lead
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus
Role: lead
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Role: lead
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Role: lead
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
Role: lead
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Role: lead
F01 in the Treatment of Autoimmune Diseases
Role: collaborator
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
Role: lead
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
Role: collaborator
All 9 trials loaded